Diem Nguyen tapped to lead 'point of in­flec­tion' at Xalud Ther­a­peu­tics; Di­ana Es­co­lar dances her way to Avro­bio CMO

Diem Nguyen

Diem Nguyen con­sid­ers her­self a “point of in­flec­tion seer.”

Help­ing busi­ness­es strate­gize and scale up is “where my sweet spot is,” the Pfiz­er vet­er­an said. So when she was tapped to take the helm at gene ther­a­py-fo­cused Xalud Ther­a­peu­tics, she knew it would be a great fit.

Xalud, found­ed in 2009 and head­quar­tered in New York City, is work­ing on non-vi­ral gene ther­a­pies to treat patho­log­ic in­flam­ma­tion. The com­pa­ny’s lead can­di­date, XT-150, is a lo­cal­ly in­jectable plas­mid DNA gene ther­a­py ex­press­ing In­ter­leukin 10 (IL-10) — an up­stream mod­u­la­tor for many pro-in­flam­ma­to­ry and an­ti-in­flam­ma­to­ry me­di­a­tors.

Nguyen said IL-10 has evad­ed drug de­vel­op­ment for “quite a long time.” And as the com­pa­ny’s new CEO, she’s ready to “crack that chal­lenge.”

XT-150 is cur­rent­ly in a Phase II/III tri­al for os­teoarthri­tis, and Nguyen ex­pects to read out topline Phase IIb da­ta in Q4. Xalud is al­so look­ing to test its plat­form in a va­ri­ety of oth­er ar­eas, from oph­thal­mol­o­gy to neu­rol­o­gy.

“This gene ther­a­py plat­form is not for a niche pop­u­la­tion. It is ac­tu­al­ly meant for, what we like to call … gene ther­a­py for the mass­es,” Nguyen said, adding that hun­dreds of mil­lions of pa­tients could po­ten­tial­ly ben­e­fit.

Nguyen hails from PPD, a con­tract re­search or­ga­ni­za­tion where she served as ex­ec­u­tive VP. But a ma­jor­i­ty of her ca­reer (10 years of it) was spent at Pfiz­er, where she built the biosim­i­lars busi­ness unit from the ground up. Af­ter con­vinc­ing ex­ec­u­tive lead­er­ship and the board to in­vest in the unit Nguyen helped iden­ti­fy five mon­o­clon­al an­ti­bod­ies, cre­ate cell lines, then move in­to clin­i­cal de­vel­op­ment and ul­ti­mate­ly com­mer­cial­iza­tion. Biosim­i­lars is now one of Pfiz­er’s high­est growth ar­eas, she said.

From there, Nguyen took on a num­ber of dif­fer­ent com­mer­cial roles across bi­o­log­ics, sol­id oral dose, ster­ile in­jecta­bles, and de­vices across mul­ti­ple ther­a­peu­tic ar­eas. Her last role was glob­al pres­i­dent of the US, Latin Amer­i­ca and Cana­da and glob­al ster­ile in­jecta­bles for Pfiz­er Es­sen­tial Health.

Nguyen said all that ex­pe­ri­ence makes her well equipped to see and build on Xalud’s po­ten­tial.

“We have been work­ing on re­al­ly try­ing to bring this great sci­ence to a de­gree that I think it de­serves for pa­tients that are suf­fer­ing,” she said. —Nicole De­Feud­is 


Di­ana Es­co­lar

Avro­bio an­nounced a key new hire in nam­ing Di­ana Es­co­lar as chief med­ical of­fi­cer this past Tues­day. But many years ago, Es­co­lar had imag­ined her­self in a dif­fer­ent ca­reer en­tire­ly.

Es­co­lar spent much of her child­hood and young adult life as a bal­le­ri­na, and by age 22 had reached what she con­sid­ered the pin­na­cle of her danc­ing pas­sion — per­form­ing in a show of the Bal­lad of Don Quixote in San Ju­na, Ar­genti­na. Ul­ti­mate­ly, she was of­fered a po­si­tion as a pro­fes­sion­al dancer in one of the world’s pre­miere bal­let com­pa­nies.

Hav­ing reached all she set out to do in bal­let, she in­stead went in­to med­i­cine, look­ing for a new chal­lenge.

“I love chal­lenges, I love to achieve things,” Es­co­lar told End­points News. “When I get to the top, I en­joy it for a lit­tle while and then go ‘what’s next?’ That’s sort of what hap­pened. I was a gift­ed bal­le­ri­na, I worked very hard to get where I was, it was a love and pas­sion.”

Es­co­lar said there wasn’t a spe­cif­ic mo­ment where she re­al­ized she wants to change ca­reer paths. It was more of a grad­ual re­al­iza­tion, with the un­der­stand­ing that danc­ing pro­fes­sion­al­ly ul­ti­mate­ly re­sults in a short ca­reer, and most end up as danc­ing teach­ers or chore­o­g­ra­phers. That’s where she’d be at this point in her life had she gone in the oth­er di­rec­tion, she says.

While grow­ing up, Es­co­lar had her hands in many ac­tiv­i­ties as a stu­dent. She took bi­ol­o­gy and chem­istry class­es at the Uni­ver­si­ty of Buenos Aires, hav­ing al­ways been in­ter­est­ed in the sci­ences. She stud­ied Eng­lish, Ger­man and French, none of which were her na­tive lan­guage. She even played gui­tar and was in a band.

In med school, Es­co­lar set­tled on neu­ro­sciences be­cause “it was one of the few things that didn’t make me fall asleep.” She en­joyed learn­ing how CNS dis­eases could af­fect the whole body and man­i­fest in dif­fer­ent ways, set­ting a new goal to help pa­tients in these ar­eas and en­sure that care could be ad­min­is­tered eq­ui­tably around the world.

That even­tu­al­ly led to co-found­ing the Co­op­er­a­tive In­ter­na­tion­al Neu­ro­mus­cu­lar Re­search Group in 1999, which cre­at­ed a cen­tral in­fra­struc­ture for sci­en­tif­ic, trans­la­tion­al, and clin­i­cal re­search in neu­ro­mus­cu­lar dis­eases. Es­co­lar con­sid­ers this her Quixote per­for­mance in the in­dus­try.

“That com­plete­ly changed the land­scape of drug tri­als and ad­vance­ment of treat­ment for all the neu­ro­mus­cu­lar and neu­ro­ge­net­ic dis­or­ders,” Es­co­lar said. “There’s been a lot of the in­dus­try that fol­lowed that, and the Eu­ro­peans cre­at­ed a sim­i­lar net­work that end­ed up part­ner­ing with CIN­RG, so it be­came a glob­al net­work.”

In the ear­ly 2010s, she then went in­to the pri­vate sec­tor, most re­cent­ly serv­ing as CMO at the now-for­mer mi­Ra­gen Ther­a­peu­tics. — Max Gel­man


Jonathan Vi­o­lin

Virid­i­an Ther­a­peu­tics was bought out in Oc­to­ber by mi­rA­gen, and now the lat­ter has de­cid­ed to change its name to Virid­i­an — and change its top ex­ec. Virid­i­an co-founder Jonathan Vi­o­lin, who had been pres­i­dent and COO, will rosin up the bow as pres­i­dent and CEO af­ter his pre­de­ces­sor’s very brief tenure. Lee Rauch had been named CEO of Boul­der, CO-based mi­rA­gen in Sep­tem­ber af­ter ini­tial­ly com­ing on board in June as COO, and she will now be a strate­gic ad­vi­sor. Vi­o­lin co-found­ed Treve­na and served in var­i­ous ca­pac­i­ties there, in­clud­ing SVP, sci­en­tif­ic af­fairs and in­vestor re­la­tions of­fi­cer.

Virid­i­an is al­so boost­ing the lead­er­ship team with Bar­rett Katz as CMO. Katz was with two sub­sidiaries at Bridge­Bio: pres­i­dent and CMO of Reti­na­genix and CEO of For­ti­fy Ther­a­peu­tics. Pri­or to that, he was CMO at Gen­Sight Bi­o­log­ics.

→ Just a cou­ple weeks af­ter its lead drug IMR-687 failed to im­press in a Phase IIa tri­al for sick­le cell dis­ease — send­ing shares tum­bling — Imara has re­cruit­ed Ken­neth At­tie as CMO. At­tie, who cut his teeth as a clin­i­cal sci­en­tist at Genen­tech, was pre­vi­ous­ly Ac­celeron’s VP of med­ical re­search for more than 11 years, steer­ing glob­al clin­i­cal de­vel­op­ment of such drugs as Re­blozyl (lus­pa­ter­cept), which could have block­buster po­ten­tial.

Frank Neu­mann

→ In a sur­pris­ing about-face, Frank Neu­mann has stepped away as Ve­rastem’s CMO af­ter on­ly two blink-and-you-miss-it weeks on the job, prompt­ing their stock $VSTM to slide 10% on Wednes­day af­ter the an­nounce­ment. Neu­mann was just in last week’s Peer Re­view af­ter tak­ing the Ve­rastem job and leav­ing his po­si­tion as VP, head of on­col­o­gy clin­i­cal re­search at blue­bird bio. Ve­rastem can on­ly say that Neu­mann “ac­cept­ed a role at a cell ther­a­py com­pa­ny to con­tin­ue work in that space.”

Amir Re­ich­man

Biond­Vax’s com­plete mis­fire in a Phase III study of its uni­ver­sal flu vac­cine sent in­vestors to the hills — and sig­naled a chang­ing of the guard at CEO. With Ron Babecoff no longer at the helm of the place he co-found­ed, Amir Re­ich­man steps in ef­fec­tive March 2, while Babecoff tran­si­tions to a se­nior ad­vi­so­ry role. In the mean­time, Re­ich­man will wrap up his run as GSK’s head of glob­al vac­cines en­gi­neer­ing core tech­nolo­gies and as­set man­age­ment. Re­ich­man’s tenure pre­dates the 2015 ac­qui­si­tion of No­var­tis Vac­cines, where he held posts in the glob­al vac­cines sup­ply chain man­age­ment or­ga­ni­za­tion.

Anil Sing­hal

Tizona spin­out Tr­ishu­la Ther­a­peu­tics, which is part­ner­ing with Ab­b­Vie on their an­ti-CD39 an­ti­body TTX-030, has se­lect­ed Anil Sing­hal as CEO. Tizona CEO Scott Clarke had been in­ter­im CEO of Tr­ishu­la, which launched last Au­gust. It’s a fa­mil­iar face to their part­ner: Sing­hal was once Ab­b­Vie’s VP of ear­ly on­col­o­gy de­vel­op­ment and head of the phar­ma gi­ant’s site in Red­wood City, CA. He was CEO of Adicet Bio for two years un­til it merged with No­var­tis spin­out reSTOR­bio last spring, leav­ing its CEO Chen Schor to take the helm at Adicet.

→ Big Phar­ma vet Michael Flana­gan has been in­stalled as chief tech­ni­cal of­fi­cer at an­ti­body oligonu­cleotide con­ju­gate out­fit Avid­i­ty Bio­sciences, part­ner­ing with CSO Art Levin “to deep­en the pipeline and broad­en the AOC plat­form,” pres­i­dent and CEO Sarah Boyce said in a state­ment. Flana­gan had pre­vi­ous­ly been Genen­tech’s se­nior di­rec­tor and project team leader, on­col­o­gy and im­munol­o­gy, and be­fore that, he was se­nior di­rec­tor of RNA sci­ences at Mer­ck. In the 1990s, Flana­gan was a se­nior sci­en­tist at Gilead.

Thomas Soloway

Ver­sant-backed T cell ther­a­py play­er T-knife, which pulled in a Se­ries A worth more than $78 mil­lion in the dog days of last sum­mer, is re­fash­ion­ing its C-suite with Thomas Soloway as CEO and Camille Lan­dis as CBO and CFO. Soloway, who re­places Elisa Kieback, had logged five years at Au­dentes as their EVP, COO and had a brief run as CFO at As­cendis Phar­ma AS from 2014-15. Lan­dis heads to T-knife from Uni­ty Biotech­nol­o­gy, where she was SVP, cor­po­rate de­vel­op­ment, and she’s al­so been CBO at Ei­dos.

→ In ad­di­tion to Lan­dis at T-knife, the ex­o­dus from Uni­ty Biotech­nol­o­gy con­tin­ues af­ter deep job cuts and the loss of their lead pro­gram cast a pall on their 2020. Dou­glas Rich has be­come chief tech­ni­cal of­fi­cer at Ap­plied Mol­e­c­u­lar Trans­port, a South San Fran­cis­co biotech which raised a shade more than $177 mil­lion in a June IPO. Rich had been with Uni­ty since 2017 as SVP, op­er­a­tions, and has ex­pe­ri­ence from Kythera Bio­phar­ma­ceu­ti­cals (SVP, op­er­a­tions), Boehringer In­gel­heim (VP, qual­i­ty) and Am­gen in sev­er­al op­er­a­tions roles spread over 18 years.

Jim Caggiano

→ Just a short time ago, Jim Caggiano took the CEO reins at Targazyme. Now he’s ready for an­oth­er CEO chal­lenge at Evolve Bi­o­log­ics, an out­fit from On­tario fo­cused on plas­ma-de­rived ther­a­peu­tics. Caggiano helmed Den­dreon and was pres­i­dent of Valeant Phar­ma­ceu­ti­cals, which sold Den­dreon to San­pow­er Group in ear­ly 2017. He’s al­so been a sales and mar­ket­ing ex­ec at Al­ler­gan and Ab­bott.

→ With its sights set on an $86 mil­lion IPO, Nex­Im­mune hired Jerome Zeld­is as their new R&D chief ear­li­er this month, and a fel­low Cel­gene alum will join him as CMO. Robert Knight spent 16 years as a VP in clin­i­cal re­search at Cel­gene and then took charge of the Yescar­ta clin­i­cal pro­gram at Kite. Be­fore these stops, Knight was Sor­ren­to’s head of clin­i­cal re­search. Phase I/II tri­als are on­go­ing for Nex­Im­mune’s lead can­di­dates NEXI-001 and NEXI-002.

Else­where at Nex­Im­mune, Grant Ver­standig has been elect­ed to the Gaithers­burg, MD biotech’s board of di­rec­tors. Ver­standig is the chief dig­i­tal of­fi­cer at Unit­ed­Health Group, which ac­quired his com­pa­ny Ral­ly Health in 2017.

Hen­ri­et­ta Uk­wu

→ Mean­while, at an­oth­er promi­nent Gaithers­burg biotech, No­vavax keeps on adding new folks as they push for­ward in a piv­otal Phase III with their Covid-19 vac­cine. This time it’s Hen­ri­et­ta Uk­wu mak­ing her way to No­vavax as chief reg­u­la­to­ry and qual­i­ty of­fi­cer. A Mer­ck and Pfiz­er vet in reg­u­la­to­ry af­fairs, Uk­wu de­vot­ed eight years to Ot­su­ka Phar­ma­ceu­ti­cals, where she was most re­cent­ly chief reg­u­la­to­ry of­fi­cer and glob­al head of qual­i­ty and reg­u­la­to­ry.

Christo­pher Mox­ham logged al­most 20 years in two sep­a­rate stints in drug dis­cov­ery at Eli Lil­ly de­vel­op­ing the phar­ma gi­ant’s on­col­o­gy pipeline be­fore swing­ing to Ful­crum Ther­a­peu­tics two years ago as SVP, dis­cov­ery re­search. Now Ful­crum, which saw its Phase II study fal­ter with old GSK drug losmapi­mod last sum­mer, has pro­mot­ed Mox­ham to CSO. He re­places fel­low Eli Lil­ly alum Owen Wal­lace, who was Ful­crum’s chief sci­en­tist since 2017.

Kel­ly Mac­Don­ald

Michael Os­tra­ch an­nounced his re­tire­ment last fall as CFO of Dy­navax, and this week the hep B vac­cine mak­er named Kel­ly Mac­Don­ald as his suc­ces­sor. Mac­Don­ald hails from Iron­wood Phar­ma­ceu­ti­cals, where she held a va­ri­ety of ti­tles, be­gin­ning as a se­nior man­ag­er, tech­ni­cal ac­count­ing and ex­ter­nal re­port­ing and cap­ping her time as chief ac­count­ing of­fi­cer and VP, fi­nance.

John Doyle has been ap­point­ed CFO at Chi­as­ma, which won FDA ap­proval back in June for its acromegaly drug My­capssa. He suc­ceeds Mark Fitz­patrick, who will stick around as a con­sul­tant un­til June 30. Doyle ar­rives at Chi­as­ma from a near­ly three-year stint at Ve­rastem, even­tu­al­ly be­com­ing the can­cer biotech’s VP of fi­nance and in­vestor re­la­tions.

Matthew Plun­kett

Snap­ping up $80 mil­lion in Se­ries C fi­nanc­ing in No­vem­ber — with a hint of prep­ping an IPO some­time this year — South San Fran­cis­co blood can­cer biotech Ima­go Bio­Sciences has pegged Matthew Plun­kett as CFO. Plun­kett is com­ing off a two-year run as CFO for Nkar­ta Ther­a­peu­tics, and he’s al­so been chief fi­nan­cial and busi­ness of­fi­cer at Mede­or Ther­a­peu­tics.

Fred­er­ic Fasano has been named pres­i­dent and COO of Que­bec-based Va­leo Phar­ma, cen­tered on com­mer­cial­iz­ing pre­scrip­tion prod­ucts in Cana­da. Fasano, a long­time Servi­er vet who even­tu­al­ly climbed his way to CEO of Servi­er Cana­da from 2011-20, will al­so be a mem­ber of Va­leo’s board of di­rec­tors. At the same time, Va­leo CEO Steve Sav­iuk will slide in­to the role of vice-chair­man of the board.

Amit Mun­shi’s neu­ro sub­sidiary Long­board Phar­ma­ceu­ti­cals has a new CFO with the ar­rival of Bran­di Roberts. Roberts hails from Lin­eage Cell Ther­a­peu­tics, hold­ing the CFO post for two years un­til re­sign­ing last week. Lin­eage CEO Bri­an Cul­ley will be in­ter­im CFO there un­til a re­place­ment is found.

Else­where at Long­board, for­mer Are­na board mem­ber and ex-Idec Phar­ma­ceu­ti­cals CFO Phillip Schnei­der, along with eGe­n­e­sis CEO Paul Sekhri, have jumped on to the board of di­rec­tors.

Con­nie Chang

→ Reti­nal dis­ease-fo­cused ONL Ther­a­peu­tics from Ann Ar­bor, MI has wel­comed Con­nie Chang as their new COO. A Pfiz­er vet in mar­ket­ing, Chang was pre­vi­ous­ly VP of cor­po­rate af­fairs at Mil­len­do Ther­a­peu­tics, which is be­ing forced to re-eval­u­ate where they are as a com­pa­ny by slash­ing their staff and clos­ing up shop on NK3R an­tag­o­nist MLE-301 ear­li­er this month.

→ Bel­gian phar­ma Ox­u­ri­on NV, fo­cused on eye dis­eases con­nect­ed with di­a­betes, chose a new CFO and CMO last year, and they’ve reached in­to acad­e­mia to tap Alan Stitt as CSO. Stitt has been the chair of ex­per­i­men­tal oph­thal­mol­o­gy at Queen’s Uni­ver­si­ty Belfast since 2001 and has spe­cial­ized in re­search­ing reti­nal dis­eases. Stitt suc­ceeds the re­tir­ing Jean Feyen, who had been Ox­u­ri­on’s CSO since 2013.

Quentin Mc­Cub­bin

→ With its lead drug FX-322 tar­get­ing sen­sorineur­al hear­ing loss, Fre­quen­cy Ther­a­peu­tics has in­stalled Quentin Mc­Cub­bin as chief man­u­fac­tur­ing of­fi­cer, a month and a half af­ter Pe­ter Pfre­und­schuh was ap­point­ed CFO. Mc­Cub­bin hails from Tony Coles’ team at Cerev­el, where he led their tech­ni­cal op­er­a­tions. He al­so had a 19-year tenure with Take­da/Mil­len­ni­um, with the last three-and-a-half years as VP, glob­al head of chem­i­cal de­vel­op­ment lab­o­ra­to­ries.

→ Dutch biotech Sapreme, fo­cused on de­vel­op­ing macro­mol­e­cule ther­a­peu­tics, has cor­ralled Hen­rik Luessen as CBO. Luessen has pre­vi­ous­ly been CBO at Bel­gian cell ther­a­py de­vel­op­er Promethera Bio­sciences and start­ed life sci­ence ad­vi­so­ry group Ty­to­nis BV, serv­ing as man­ag­ing di­rec­tor.

Car­la Poul­son

Car­la Poul­son’s re­cent stop at Akcea was a brief one as she moves on to an­ti­body-drug con­ju­gate (ADC) play­er Mer­sana Ther­a­peu­tics as chief hu­man re­sources of­fi­cer. As Peer Re­view told you, Poul­son left Ver­tex last May to join Akcea in the same role she now fills at Mer­sana. In Poul­son’s near­ly decade-long stay at Ver­tex, she was head of in­ter­na­tion­al hu­man re­sources and was lat­er pro­mot­ed to VP, hu­man re­sources.

Richard Wood­man

Ei­sai has named Richard Wood­man as chief clin­i­cal of­fi­cer of its on­col­o­gy busi­ness group. Most re­cent­ly, Wood­man was CMO and head of re­search and de­vel­op­ment at On­cono­va Ther­a­peu­tics. Pri­or to that, Wood­man had a 12-year stint at No­var­tis, serv­ing as fran­chise head for hema­tol­ogy in glob­al med­ical af­fairs. Wood­man jumped in­to the in­dus­try as se­nior med­ical di­rec­tor at J&J.

Zim­mer Bio­met has en­list­ed El­li­son (El­lie) M Humphrey as chief trans­for­ma­tion of­fi­cer. Humphrey hails from Medtron­ic, where she most re­cent­ly served as VP of en­ter­prise ex­cel­lence and busi­ness trans­for­ma­tion.

Steven Tuch has been cho­sen as head of cor­po­rate de­vel­op­ment at Rally­bio, which has $145 mil­lion in Se­ries B fi­nanc­ing squared away for pro­grams that in­clude RLYB211 for fe­tal and neona­tal al­loim­mune throm­bo­cy­tope­nia. Tuch leaves his gig at BMO Cap­i­tal Mar­kets as man­ag­ing di­rec­tor, head of US eq­ui­ty cap­i­tal mar­kets orig­i­na­tions.

Gwe­nan White

→ Ef­fec­tive in March, Big Phar­ma vet Gwe­nan White will join Ipsen — now helmed by for­mer Sanofi ex­ec David Loew — as EVP, com­mu­ni­ca­tions and pub­lic af­fairs. White, who’s worked in com­mu­ni­ca­tions at GSK, Ab­bott and Ab­b­Vie, is com­ing from No­var­tis, where she was glob­al head of phar­ma com­mu­ni­ca­tions and pa­tient ad­vo­ca­cy.

Jean-Pierre Som­ma­dos­si’s crew at Atea Phar­ma­ceu­ti­cals has added two new ex­ecs, start­ing with SVP of reg­u­la­to­ry af­fairs Jayan­thi Wolf. A 19-year Mer­ck alum, Wolf closed her time at the phar­ma gi­ant as ex­ec­u­tive di­rec­tor, glob­al reg­u­la­to­ry af­fairs. In ad­di­tion, Atea has se­lect­ed Jon­ae Barnes as SVP of in­vestor re­la­tions and cor­po­rate com­mu­ni­ca­tions. Barnes, who got her start at Sepra­cor (now Sunovion) from 1996-2009, had been Pox­el’s SVP, in­vestor re­la­tions, cor­po­rate com­mu­ni­ca­tions & pub­lic re­la­tions.

AGC Bi­o­log­ics, the CD­MO that com­mit­ted $194 mil­lion to ex­pand­ing its Copen­hagen site last month, has called up­on David Stew­art to over­see their site in Boul­der, CO. The new gen­er­al man­ag­er/site head comes to AGC with lead­er­ship ex­pe­ri­ence in man­u­fac­tur­ing from Bio­gen and Genen­tech.

Bryan Wahl

Tar­sus Phar­ma­ceu­ti­cals, which is de­vel­op­ing its lead drug for the eye dis­ease De­mod­ex ble­phar­i­tis, has made Bryan Wahl gen­er­al coun­sel, a cou­ple weeks af­ter the ap­point­ment of chief hu­man re­sources of­fi­cer Di­anne Whit­field. Wahl was for­mer­ly a part­ner at Knobbe Martens since 2005.

Black Di­a­mond Ther­a­peu­tics has made the ad­di­tion of Kapil Dhin­gra to its board of di­rec­tors. Dhin­gra served as clin­i­cal and strate­gic ad­vi­sor to the com­pa­ny since 2017. Dhin­gra joins with near­ly a decade of ex­pe­ri­ence at Roche, serv­ing in roles such as VP, head of on­col­o­gy dis­ease bi­ol­o­gy lead­er­ship team and head of on­col­o­gy clin­i­cal de­vel­op­ment. His ap­point­ment comes months af­ter Black Di­a­mond reeled in ex-GSK CEO Bob In­gram as chair­man for its board.

John McHutchi­son

→ Ox­ford-based ex­o­some play­er Evox Ther­a­peu­tics has re­served a seat for John McHutchi­son on the board of di­rec­tors. Since Au­gust 2019, McHutchi­son has been pres­i­dent and CEO at As­sem­bly Bio­sciences af­ter nine years at Gilead.

SOPHiA GE­NET­ICS has nom­i­nat­ed Kathy Hi­bbs to their board of di­rec­tors. Cur­rent­ly, Hi­bbs is chief le­gal and reg­u­la­to­ry of­fi­cer at 23andMe. Hi­bbs al­so sits on the boards of Ge­nom­ic Health and Mono­gram Bio­sciences.

Al­i­son Law­ton

→ Launched by Syn­cona, AAV-based gene ther­a­py shop Swan­Bio has wel­comed Al­i­son Law­ton to their board of di­rec­tors fol­low­ing the No­vem­ber ap­point­ments of Pat­ty Allen, Dan­ny Bar-Zo­har and Alex Hamil­ton. The for­mer pres­i­dent and CEO of Kalei­do Bio­sciences, Law­ton al­so joined the board of X4 Phar­ma­ceu­ti­cals in Oc­to­ber.

CMR Sur­gi­cal has tapped Cather­ine Moukheibir as non-ex­ec­u­tive di­rec­tor. Moukheibir joins the com­pa­ny with ex­pe­ri­ence as non-ex­ec­u­tive di­rec­tor of Iron­wood Phar­ma­ceu­ti­cals, Kymab and Or­p­hazyme. Pre­vi­ous­ly, Moukheibir was CFO of Movetis NV (ac­quired by Shire in 2010).

Hi­ber­Cell has made two new ad­di­tions to its sci­en­tif­ic ad­vi­so­ry board. Lisa Coussens will be join­ing the board with Ronald Wek. Coussens is chair of the de­part­ment of cell, de­vel­op­men­tal and can­cer bi­ol­o­gy and as­so­ciate di­rec­tor for ba­sic re­search at the Knight Can­cer In­sti­tute at Ore­gan Health & Sci­ences Uni­ver­si­ty. Mean­while, Wek is the Showal­ter pro­fes­sor of bio­chem­istry at In­di­ana Uni­ver­si­ty School of Med­i­cine.

The top 100 bio­phar­ma VCs, Bob Brad­way places $2B bet in can­cer, gene edit­ing pi­o­neer's new big idea, and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Before diving in, we had some news to share: Endpoints is launching a premium weekly report focusing on all things regulatory. Coverage will be led by our new senior editor, Zachary Brennan, who joins us from POLITICO. Arsalan Arif has more details in his Publisher’s Note.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.

Robert Bradway (Photographer: Scott Eisen/Bloomberg via Getty Images)

UP­DAT­ED: Am­gen snaps up can­cer drug play­er Five Prime, adding PhI­II-ready FGFR2b drug in $2B M&A play

Amgen is making a long-awaited move on the M&A side, buying South San Francisco-based Five Prime $FPRX for close to $2 billion and adding a slate of new cancer drugs to the pipeline.

Amgen is paying $38 a share, putting the deal value at $1.9 billion. The stock closed at $21.26 last night, giving investors a 78% premium.

The jewel in the crown of this deal is bemarituzumab, which Amgen describes as a first-in-class, Phase III-ready anti-FGFR2b antibody. Amgen was drawn to the bargaining table by Five Prime’s mid-stage data on gastric cancer, satisfied by PFS and OS data helping to validate FGFR2b as a target. Amgen researchers will now expand on the R&D program in other epithelial cancers, including lung, breast, ovarian and other cancers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.

David Liu (Casey Atkins Photography courtesy Broad Institute)

David Liu has a new big idea: pro­teome edit­ing. It could one day shred tau, RAS and some of the worst dis­ease-caus­ing pro­teins

Before David Liu became famous for inventing new forms of gene editing, he was known around academia in part for a more obscure innovation: a Rube Goldberg-esque system that uses bacteria-infecting viruses to take one protein and turn it into another.

Since 2011, Liu’s lab has used the system, called PACE, to dream up fantastical new proteins: DNA base editors far more powerful than the original; more versatile forms of the gene editor Cas9; insecticides that kill insecticide-resistant bugs; enzymes that slide synthetic amino acids into living organisms. But they struggled throughout to master one of the most common and powerful proteins in the biological world: proteases, a set of Swiss army knife enzymes that cut, cleave or shred other proteins in everything from viruses to humans.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

The 2021 top 100 bio­phar­ma in­vestors: As the pan­dem­ic hit and IPOs boomed, VCs swung in­to ac­tion like nev­er be­fore

The global pandemic may have roiled economies, killed hundreds of thousands and throttled entire industries, but the only effect it had on biopharma venture investing was to help turbocharge the field to giddy new heights.

Below you’ll find the new top 100 venture investors in the industry, ranked by the number of deals they were publicly involved in, as tracked by DealForma chief Chris Dokomajilar. The numbers master then calculated the estimated amount of money they put into each deal — divvying up the cash by the number of players — to indicate how they managed their syndicates.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bruce Cozadd, Jazz CEO (Jazz Pharmaceuticals)

Jazz CEO Bruce Cozadd cam­paigned for 6 months to buy GW Phar­ma. A 90% pre­mi­um sealed the deal — along with $17.6M in ‘re­ten­tion’ in­cen­tives

Jazz CEO Bruce Cozadd didn’t beat around the bush.

In his first video meeting with GW Pharma chief Justin Gover last July 8, he offered to pay $172 a share to get the company, which had beaten the odds in getting its remarkable cannabinoid drug Epidiolex across the regulatory finish line for epilepsy. GW’s stock closed at $129 that day.

Cozadd had already done his homework on the financing to make sure he could swing it the way he wanted. He just needed to do some due diligence before making the non-binding bid firm.

UP­DAT­ED: Not 3 weeks af­ter tak­ing Hu­ma­cyte pub­lic, Ra­jiv Shuk­la launch­es an­oth­er blank check com­pa­ny

One of biotech’s earliest SPAC investors is back with another blank-check company, less than a month after his last effort announced its intent to merge.

Rajiv Shukla is intending to take a third lucky winner public with Alpha Healthcare Acquisition III, filing to go public Thursday with a $150 million raise penciled in. The move comes just a couple of weeks after Shukla’s second SPAC said it would jump to Nasdaq in tandem with Laura Niklason’s Humacyte in a $255 million new investment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.

Genen­tech gains clin­i­cal de­vel­op­ment ex­ec by ap­point­ing Lil­li Petruzzel­li; Paul Sekhri caps event­ful week, nam­ing Sap­na Sri­vas­ta­va CFO of eGe­n­e­sis

→ A spokesperson for Genentech tells Endpoints News that Lilli Petruzzelli has forged a new path this week as SVP, early clinical development at Genentech’s Research and Early Development organization (gRED). Petruzzelli just spent two years as Incyte’s group VP, early clinical development, and prior to Incyte, she was global head, translational clinical oncology at the Novartis Institutes of Biomedical Research.

Paul Hudson, Getty Images

How does Paul Hud­son's $13.5M comp pack­age stack up against oth­er CEOs? He's in the 'first quar­tile'

Paul Hudson arrived at Sanofi like a hurricane, chopping off duds in the pipeline, shaking up the C-suite, striking big M&A deals and jumping into the Covid-19 vaccine race — all in an attempt to reboot a pharma giant notorious for its setbacks.

Now, we’re getting a look at what the CEO brought home in his first year on the job.

When all is said and done, Hudson will have made about $6.7 million in 2020, about $2.5 million of which has already been paid. The bigger figure includes a $2.3 million bonus that’s subject to approval at an April meeting, and another $1.8 million in variable compensation that has yet to be paid.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.

Af­ter three years of courtship (and turn­downs), Mer­ck pounced on the first glance of clin­i­cal da­ta in $1.85B Pan­dion takeover

It’s almost become cliché for biotech executives to talk about the importance of keeping your options open and being prepared to go all the way. But when it comes to negotiating with a giant like Merck, a little patience can indeed go a long way.

Just ask Pandion Therapeutics.

Days ago we already learned that Merck is shelling out $1.85 billion to pick up the biotech and its slate of autoimmune hopefuls. What we didn’t know until the SEC disclosure dropped Thursday is that the deal comes after Pandion turned down two other proposals from Merck over the past three years and held out until the last minute for a sweetened deal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.